Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 8Phase 3 6Phase 4 3Phase 1/2 2Phase 2/3 1

Status

Completed 4Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Endocrine 5Gastrointestinal 3NET 2Lymphoid 1

Conditions

Pituitary Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Acromegaly 2Pancreatic Neoplasms 1Lymphoma, Follicular 1Growth Disorders 1Gigantism 1Carcinoid Tumor 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × pasireotide × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01137682 2018-04-05

PAOLA

Novartis

Phase 3 Completed
198 enrolled 17 charts
Endocrine

Acromegaly, Pituitary Neoplasms

NCT00994110 2016-02-01

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
439 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00690430 2013-07-30

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Novartis

Phase 3 Completed
186 enrolled 11 charts
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡